Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-11-14, Stock:LLY, The news for the past five days is as follows:
2019-11-07: NEWS1: Lilly Announces the Pricing Terms of its Cash Tender Offer for Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities.NEWS2: Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up.NEWS3: Lilly Announces the Early Tender Results and Upsizing of Its Pending Cash Tender Offer to Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities.
2019-11-08: NEWS1: Aduro (ADRO) Q3 Loss Wider Than Expected, Revenues Rise Y/Y.NEWS2: Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales.NEWS3: Lilly Reinforces its Commitment to Rheumatology through Data Showcased at the ACR/ARP Annual Meeting.
2019-11-11: NEWS1: 4 Biotech Stocks That Could Keep Beating Wall Street.NEWS2: Eli Lilly Has the Base to Support a New Rally.
2019-11-12: NEWS1: Supernus Pharmaceuticals seeks FDA approval for ADHD drug.NEWS2: Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance® in people hospitalized for acute heart failure who have been stabilized.NEWS3: ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz® (ixekizumab) Versus Humira® (adalimumab) Trial in Psoriatic Arthritis.NEWS4: ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis.
2019-11-13: NEWS1: Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes.NEWS2: FDA panel votes against Lilly-Boehringer Ingelheim's diabetes drug.

Answer: Decrease